Vertex Pharmaceuticals stock: Genomics pact extended, EUR 490.55, up 0.75%
Published on 11/19/2026 at 08:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGenomics Partnership Extends
- Vertex extended its drug discovery and validation collaboration with Genomics by four years.
- The potential contract value exceeds USD 220 million and includes milestone payments and tiered royalties.
Vertex Pharmaceuticals stock traded at EUR 490.55 on Lang & Schwarz at 08:57 CET on Thursday, November 19, 2026, 0.75 percent above the Xetra close of Wednesday, November 18, at EUR 486.90.
The premarket move follows Vertex's extension of its strategic drug discovery and validation collaboration with Genomics. The four-year agreement builds on an eight-year partnership that began in 2018 and focuses on using human genetics to identify and validate drug targets and select biomarkers for precision medicines.
The potential contract value exceeds USD 220 million, according to the PR Newswire release. The amount depends on research, development, regulatory and commercial milestones and includes tiered royalties on future net sales from products resulting from the collaboration.
For Vertex, the partnership supports a research strategy built around human genetics and precision medicine. Genomics said its platform includes more than 45,000 genome-wide association studies and has helped identify more than 100 potential drug targets. Vertex also holds an equity investment in Genomics dating from 2018.
The S&P 500 provides the broader US market context for the session.
More news and analyses are available on Vertex Pharmaceuticals stock.
